Skip to main content
Home

Leading research for life changing results

  • Our Role & Impact
    • About HMRI
    • Our Team
    • Research Funded through HMRI
    • Our Foundations
      • HMRI Foundation
      • HMRI Sydney Foundation
      • HCRF
      • HTRF
      • Borne HMRI
    • Awards and Recognition
      • Researcher Awards
      • HMRI Exceptional Service
    • Our Partnerships
    • Governance
    • Careers
    • Contact Us
  • Medical Research
    • Research
    • Researchers
    • Participate In Research
    • Coronavirus (COVID-19)
  • Support HMRI
    • Donate Online
    • Your Impact
    • Ways to Donate
    • Fundraise
    • Bequests
    • Volunteer
    • Company Donors
  • For Researchers
    • HMRI Connect Researcher Intranet
    • Services for Researchers
      • Clinical Trials Unit
      • Bioinformatics & Special Applications Support
      • Clinical Research Design and Statistics
      • Health Research Economists
      • Funding Support
      • Research Study Recruitment
      • Clinical Trials Roadmap
    • Facilities and Equipment for Researchers
    • Register to be a HMRI Researcher
  • Events
    • Upcoming Events
  • News & Articles
  1. Home
  2. Search Results

Search Results

  • All (18) Remove All (18) filter
  • Research (10)
  • News & Articles (5)
  • Researcher Profiles (2)
  • General (1)

Search found 18 items

All
A new approach to treat acute myeloid leukaemia
Category: News & Articles
... discovered a new cellular mechanism that promotes the development of acute myeloid Leukaemia (AML). Researchers from the University of Newcastle, Hunter ...
Leukaemia
Category: Research
Leukaemia is a cancer of the blood or bone marrow involving abnormal ... every year. (Source – Australian Institute of Health and Welfare ) Acute Lymphoblastic Leukaemia (ALL) is one of the most deadly and most ... outcomes of patients with leukaemia. Another type of leukaemia, Acute myeloid leukaemia (AML), is a rapidly progressing blood cancer ...
Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML)
Category: Research
A new treatment for acute myeloid leukaemia Acute myeloid leukaemia (AML) is the most common and deadly type of adult leukaemia, with a ...
Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)
Category: Research
Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults, and accounts ...
Targeting BAALC as a new treatment for acute myeloid leukaemia
Category: Research
Improving survival from Acute myeloid leukaemia (AML) with new therapies Acute myeloid leukaemia (AML) is the ...
Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia
Category: Research
Finding the ‘disease-causing’ mutations and proteins in Acute Myeloid Leukaemia to develop new treatment strategies. Acute Myeloid Leukaemia ...
Developing new treatments for resistance in acute myeloid leukaemia
Category: Research
Treatment for the most common and deadly form of blood cancer (acute myeloid leukaemia) hasn’t changed in over 40 years. New treatments fail ...
Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS
Category: Research
AML (acute myeloid leukemia) is a very aggressive form of leukemia. ... future. Research Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of ...
Nikki Verrills
Category: Researcher Profiles
... to all cancer types, but I focus primarily on two diseases: Acute myeloid leukaemia (AML) – the most common adult leukaemia, with a dismal 5year ...
Re-purposing PARP inhibitors to treat childhood leukaemias
Category: Research
... is the most common cause of childhood disease-related deaths, with leukaemia the most common childhood cancer in Australia. The two most common forms of leukaemia in children are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Whilst remission is achievable in over 95% of ...
  • 1
  • 2
  • Contact us
  • View Research & Diseases
  • News & Articles
  • Site Map
  • Privacy Policy
  • ​
  • HUNTER MEDICAL RESEARCH INSTITUTE ABN 27 081 436 919 | Phone (02) 4042 0000 |  Donation Hotline 1300 993 822
  •  
  • Copyright © Hunter Medical Research Institute 2022
  •  
  • Tata Consultancy Services